Results 81 to 90 of about 1,627,756 (267)

Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update

Hepatology International, 2017
There is great geographical variation in the distribution of hepatocellular carcinoma (HCC), with the majority of all cases worldwide found in the Asia–Pacific region, where HCC is one of the leading public health problems.
M. Omata, A. Cheng, N. Kokudo, M. Kudo, J. Lee, J. Jia, R. Tateishi, K. Han, Y. K. Chawla, S. Shiina, W. Jafri, D. Payawal, Takamasa Ohki, S. Ogasawara, Pei‐Jer Chen, C. Lesmana, L. Lesmana, R. Gani, S. Obi, A. Dokmeci, S. Sarin   +20 more
semanticscholar   +1 more source

Integrin β4‐Enriched Small Extracellular Vesicle as Drug Delivery Vehicle for Targeting Pulmonary Metastasis of Hepatocellular Carcinoma

Advanced Healthcare Materials, EarlyView.
The expression of integrin β4 (ITGβ4) on small extracellular vesicle (sEV) correlates with lung‐tropism. Enrichment of ITGβ4 on sEVs enhances their lung‐targeting ability. The sEVs loaded with doxorubicin exhibit superior therapeutic efficacy in a lung metastasis mouse model.
Tung Him Ng, Aijun Liang, Maximus CF Yeung, Sze Keong Tey, Kam‐Leung Siu, Sin‐Yee Fung, Dong‐Yan Jin, Judy Wai Ping Yam   +7 more
wiley   +1 more source

State‐of‐the‐Art, Insights, and Perspectives for MOFs‐Nanocomposites and MOF‐Derived (Nano)Materials

Advanced Materials, EarlyView.
Different approaches to MOF‐NP composite formation, such as ship‐in‐a‐bottle, bottle‐around‐the‐ship and in situ one‐step synthesis, are used. Owing to synergistic effects, the advantageous features of the components of the composites are beneficially combined, and their individual drawbacks are mitigated.
Stefanos Mourdikoudis, Subhajit Dutta, Saqib Kamal, Sergio Gómez‐Graña, Isabel Pastoriza‐Santos, Stefan Wuttke, Lakshminarayana Polavarapu   +6 more
wiley   +1 more source

Advances and Strategies in Enhancing mRNA Cancer Vaccines

Advanced Materials, EarlyView.
Messenger RNA (mRNA) vaccines offer a powerful approach for cancer immunotherapy, but their clinical impact remains limited by delivery challenges and suboptimal immune activation. This review discusses key biological barriers and design strategies—including structural optimization, immunomodulation, organ targeting delivery, and advanced nanocarriers ...
Miao Zhang, Shengqi Chen, Haijun Hu, Yenhui Ong, Qianqian Ni   +4 more
wiley   +1 more source

Heterogeneity Landscape of Circulating Tumor Cells in Clinical Utility

Advanced Therapeutics, EarlyView.
This study reports the heterogeneity spectrum of circulating tumor cells. The factors involved in the spectrum promote CTCs to overcome barriers in the metastatic cascade but impact the clinical outcome of cancer patients. In summary, the heterogeneities in association with CTCs ultimately reduce patient survival and facilitate increasing mortality of ...
Md Kowsar Alam, Lu Yanjun, Bee Luan Khoo, Tongxu Si, Heng Zou, Mengsu Yang   +5 more
wiley   +1 more source

Microphysiological Systems in Cancer Research: Advancing Immunotherapy through Tumor Microenvironment‐Integrated Organ‐On‐Chip Models

Advanced Therapeutics, EarlyView.
Emerging microphysiological systems reproduce the spatial, biochemical, and cellular complexity of the tumor microenvironment, surpassing 2D cultures and murine models. By integrating patient‐derived tumors, perfusable vasculature, and immune trafficking, these organ‐on‐chip platforms reveal mechanisms of immune evasion, predict therapeutic responses ...
Fabiana Moresi, Francesco Noto, Jyothsna Vasudevan, Xavier Bisteau, Giulia Adriani, Andrea Pavesi   +5 more
wiley   +1 more source

Integrating bulk and single-cell RNA sequencing reveals SH3D21 promotes hepatocellular carcinoma progression by activating the PI3K/AKT/mTOR pathway.

PLoS ONE
As a novel genetic biomarker, the potential role of SH3D21 in hepatocellular carcinoma remains unclear. Here, we decipher the expression and function of SH3D21 in human hepatocellular carcinoma. The expression level and clinical significance of SH3D21 in
Wangxia Tong, Na Qin, Tao Lu, Li Liu, Rong Liu, Jibing Chen, Ning Luo   +6 more
doaj   +1 more source

HNF-4α inhibits hepatocellular carcinoma cell proliferation through mir-122-adam17 pathway.

PLoS ONE, 2020
Hepatocellular carcinoma (HCC) is one of the most common human cancers, its prevalence and severity need us to discover novel early diagnostic biomarkers and new therapeutic strategies. MicroRNA-122 is the most abundant microRNA in the liver, and acts as
Guang Yang, Min Zhang, Yawei Zhao, Yue Pan, Mujie Kan, Jing Li, Kan He, Xuewen Zhang   +7 more
doaj   +1 more source

Genetic Engineering Methods in Primary T Cells

Advanced Therapeutics, EarlyView.
Primary T cells can be engineered to confer them with novel therapeutic functions, allowing them to treat a variety of conditions. Genetic engineering can be either stable or transient, aiming to either express or inhibit a target gene. This review discusses the various genetic engineering tools available as well as their characteristics and ...
Anthony Youssef, Hui‐Shan Li
wiley   +1 more source

Clinical and pathological evaluation of fibrolamellar hepatocellular carcinoma: a single center study of 21 cases

Clinics, 2015
OBJECTIVES: Fibrolamellar hepatocellular carcinoma is a rare primary malignant liver tumor that differs from conventional hepatocellular carcinoma in several aspects.
Aline Lopes Chagas, Luciana Kikuchi, Paulo Herman, Regiane S.S.M. Alencar, Claudia M. Tani, Márcio Augusto Diniz, Vincenzo Pugliese, Manoel de Souza Rocha, Luiz Augusto Carneiro D′Albuquerque, Flair Jose Carrilho, Venancio A.F. Alves   +10 more
doaj   +1 more source